Prof John Zalcberg (Co-Chair)
Professor John Zalcberg was the Director, Division of Cancer Medicine, at the Peter MacCallum Cancer Centre in Melbourne, Australia for 17 years prior to recently taking up the position of Professor of Cancer Research in the School of Public Health and Preventative Medicine at Monash University.
After earning a Bachelor of Medicine and Bachelor of Surgery from the University of Melbourne and a PhD in cancer immunology, he served as Director of Medical Oncology at the Heidelberg Repatriation Hospital and as Director of Cancer Services at the Austin and Repatriation Medical Centre.
A founder of the Lorne Cancer Conference and the Australasian Gastrointestinal Trials Group (AGITG), he is immediate past Chair of the Board of AGITG after serving in this role for over 15 years and a past Board Member of Cancer Trials Australia. He is the current Co-Chair of the Cancer Drugs Alliance and Interim Chair of the Australian Clinical Trials Alliance.
A past Board Member of the NSW Cancer Institute, past President of the Clinical Oncological Society of Australia, and a past Member of the Consultative Council of the Victorian Cancer Agency, he has received a Medal of the Order of Australia Award (OAM) and the 2011 Cancer Achievement Award from the Medical Oncology Group of Australia.
Professor Zalcberg’s clinical research interests include gastrointestinal cancer and health care outcomes. He has published more than 230 articles in peer-reviewed journals. He was a Principal Investigator for the EORTC advanced GIST trial in Australia and continues an active involvement in trials in this disease as well as other GI cancers. He continues an active clinical practice in GI cancer.
Richard Vines (Co-Chair)
In 2001 Richard left the IT industry and has since worked in a number of not for profits variously associated with retail, politics and health. In 2012 Richard and his wife, Kate, established Rare Cancers Australia, a patient advocacy group that is focused on Australians with rare and less common cancers.
Christoph, General Manager Novartis Oncology for Australia and NZ, has spent 20 years in the pharmaceutical industry. His focus has been on bringing new innovative therapies to patients in Ophthalmology and for the last 8 years in Oncology. During his career he worked in Switzerland, Colombia, Germany and Italy in different positions mainly in the commercial field. He and his family live now in Sydney.
Ian Black is the Business Unit Head for the Oncology and Haematology portfolio at Roche Products.
Ian has worked in the Australian pharmaceutical industry for 20 years in numerous sales and marketing roles across a number of therapeutic areas. Patient access to new treatment options and effective reimbursement models are two of his key interest areas.
Ian has completed a Bachelor’s Degree in Science and a post-graduate certificate in Marketing.
Hayley is the CEO of Melanoma Patients Australia, a national organisation that provides support services and representation for those affected by melanoma.
Following a Bachelor of Science majoring in Microbiology and Psychology at Melbourne University and a post-graduate Diploma in Information Technology Hayley worked in various management roles including more than a decade within the cinema industry. Hayley moved to Brisbane in 2013 and is passionate about ensuring all patients can access the best treatments available.
Prof Grant McArthur
Professor Grant McArthur is co-head of the Cancer Therapeutics Program and Translational Research Laboratory at the Peter MacCallum Cancer Centre in Melbourne, Australia. He is Director of the Skin and Melanoma Clinical Service, a Fellow of the Royal Australasian College of Physicians and holds a PhD in Medical Biology. Professor McArthur is a previous recipient of the Translational Research Award of the Fondation Nelia et Amadeo Barletta and the Sir Edward Dunlop Clinical Cancer Research Fellowship of the Cancer Council of Victoria. He is national and international study co-chair of a number of clinical trials for targeted therapies.
Professor McArthur currently sits on the editorial boards of a number of Journals including the Journal of Clinical Oncology, Annals of Oncology and Anti-Cancer Drugs. His research interests include clinical trials of targeted therapeutics, molecular profiling of cancer, melanoma, cell cycle control, differentiation, oncogene addiction, gastrointestinal stromal tumour, and functional imaging. Recent work has focused on oncogene addiction driven by MYC, KIT, RAS and BRAF in a variety of malignant conditions to develop an understanding of the basic cellular mechanisms of cancer that can assist in the development and application of novel targeted cancer therapeutics. To date, Professor McArthur has published over 150 papers in peer-reviewed journals.
Carlo Montagner (Treasurer)
As the Founder & Chief Executive Officer of Specialised Therapeutics Australia, Carlo has extensive oncology medical and pharmaceutical experience in the United States, Europe, China, Japan and Australia. Before starting Specialised Therapeutics Australia, his roles included President of Abraxis Bioscience Inc; Global Head/EVP of Bayer-Schering Oncology; Global Team Leader of Sanofi-Aventis Oncology; Senior Director positions at Sanofi-Aventis subsidiaries in Japan and Australia.
After having spent many years working in oncology, Carlo and his wife believe cancer treatment is not just about drugs but rather that a holistic approach encompassing all aspects of managing a patient's well being is critical to improving outcomes. As a result, Carlo and his family are supporters of the Olivia Newton-John Cancer and Wellness Centre recently opened in Melbourne.
Dr Christopher Steer
Christopher is a medical oncologist at Border Medical Oncology In Albury Wodonga and conjoint senior lecturer at the UNSW rural clinical school, Albury campus. After completing his training in Melbourne within the Victorian Medical Oncology Training Group he travelled to London where he worked as a clinical research fellow at Kings College London and Guy’s and St Thomas’ Hospitals. Whilst in London Christopher also worked as a trial physician with the UK Medical Research Council (MRC) on clinical trials of chemotherapy in women with ovarian cancer.
Christopher grew up in the area he now lives but returned to Albury Wodonga in 2003 and remains committed to bringing best practice medical oncology to patients in rural and regional areas.
Christopher is the current president of the Private Cancer Physicians of Australia (PCPA). Christopher has served on the board of the International Society of Geriatric Oncology (SIOG) and the Medical Oncology Group of Australia (MOGA). He remains on the MOGA cancer drugs working group. Christopher's research interests include cancer care in the older adult and he is current chair of the geriatric oncology interest group of the Clinical Oncology Society of Australia (COSA).
He is an inaugural member of the editorial board of the Journal of Geriatric Oncology. He is chair of the scientific committee of the 2015 Annual Scientific Meeting of SIOG.
Dr Cecily Forsyth
Dr Cecily Forsyth has worked as a clinical haematologist on
the Central Coast of NSW for 20 years after training in haematology at Royal
Prince Alfred Hospital. She is passionate about improving rural and regional
patients’ access to disease information, education and clinical trials, and providing
educational opportunities for haematology trainees and haematology nurses. She
has participated in many sponsored and investigator-initiated clinical research
studies, particularly in haematological malignancies. Her main clinical and
research interest is myeloproliferative neoplasms and she has collaborated on
many Australian and International studies in these disorders.
Cecily is a member
of the ALLG CML and MPN Disease Group Committee and has established the Myeloproliferative
Neoplasms Registry (MPN01) on behalf of the ALLG. She is a past chair of the
Haematology Reference Committee for EviQ (Cancer Institute NSW).
Melissa McGregor is the Managing Director for
Pfizer Australia and leads the Internal Medicine Group for Innovative Health in
Melissa has worked in the healthcare industry for
more than 20 years, with extensive leadership, strategic and operational
expertise spanning a wide range of therapeutic areas in the primary, specialty
and hospital care sectors. She is a passionate advocate for the principles of
quality use of medicine, and is dedicated to ensuring clinicians and patients
have timely and affordable access to medicines.
Prior to her role at Pfizer, she
was the Managing Director for Pfizer New Zealand, during which she was a board
member of Medicines New Zealand and the American Chamber of Commerce.
Jane is a non-executive Director and CEO with 20 years’
experience in health and consumer protection. Her career spans diverse
executive leadership roles in not-for-profit organisations including peak
bodies, professional associations and charities.
Jane is CEO of Ovarian Cancer Australia, a national
consumer-focussed charity that supports
those affected by ovarian cancer, gives them a voice, facilitates research, and
raises awareness on a national scale. Jane is passionate about consumer-led
organisations and works tirelessly on improving health outcomes for women
living with ovarian cancer.
experience includes three years in Board Advisory Services at KPMG where she
authored KPMG’s flagship publication, the Company Directors Toolkit – a blue
print for high performing Boards.
serves as a non-executive Director of the Freemasons Foundation Victoria and
chairs their HR Advisory Committee. Jane has an Arts/law degree, MBA and is a
Fellow of the Australian Institute of Company Directors.